258 related articles for article (PubMed ID: 25896109)
1. Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes.
Manna S; Banerjee RK; Augsburger JJ; Al-Rjoub MF; Donnell A; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1297-305. PubMed ID: 25896109
[TBL] [Abstract][Full Text] [Related]
2. Development of chitosan and polylactic acid based methotrexate intravitreal micro-implants to treat primary intraocular lymphoma: an in vitro study.
Manna S; Augsburger JJ; Correa ZM; Landero JA; Banerjee RK
J Biomech Eng; 2014 Feb; 136(2):021018. PubMed ID: 24317155
[TBL] [Abstract][Full Text] [Related]
3. Ultrasonographical assessment of implanted biodegradable device for long-term slow release of methotrexate into the vitreous.
Manna S; Banerjee RK; Augsburger JJ; Al-Rjoub MF; Correa ZM
Exp Eye Res; 2016 Jul; 148():30-32. PubMed ID: 27181224
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive evaluation of toxicity in vitreoretinal domain following insertion of sustained release methotrexate micro-implant.
Manna S; Caixeta Faraj RQ; Riemann B; Rao MB; Nair V; Riemann CD; Augsburger JJ; Correa ZM; Banerjee RK
Exp Eye Res; 2021 Apr; 205():108505. PubMed ID: 33617850
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Toxicity Evaluation of a PLGA and Chitosan-Based Micro-Implant for Sustained Release of Methotrexate in Rabbit Vitreous.
Manna S; Donnell AM; Faraj RQC; Riemann BI; Riemann CD; Augsburger JJ; Correa ZM; Banerjee RK
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452188
[TBL] [Abstract][Full Text] [Related]
6. Improved design and characterization of PLGA/PLA-coated Chitosan based micro-implants for controlled release of hydrophilic drugs.
Manna S; Donnell AM; Kaval N; Al-Rjoub MF; Augsburger JJ; Banerjee RK
Int J Pharm; 2018 Aug; 547(1-2):122-132. PubMed ID: 29857096
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Electroretinography Assessment of Intravitreal Sustained-Release Methotrexate Microimplants in Rabbit Eyes.
Manna S; Augsburger JJ; Correa ZM; Al-Rjoub MF; Rao MB; Banerjee RK
J Ocul Pharmacol Ther; 2016 Nov; 32(9):583-594. PubMed ID: 27754738
[TBL] [Abstract][Full Text] [Related]
8. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study.
Palakurthi NK; Correa ZM; Augsburger JJ; Banerjee RK
J Ocul Pharmacol Ther; 2011 Apr; 27(2):151-6. PubMed ID: 21323470
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.
De Paiva MRB; Lage NA; Guerra MCA; Mol MPG; Ribeiro MCS; Fulgêncio GO; Gomes DA; Da Costa César I; Fialho SL; Silva-Cunha A
Doc Ophthalmol; 2019 Feb; 138(1):3-19. PubMed ID: 30456454
[TBL] [Abstract][Full Text] [Related]
10. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide.
Kim YM; Lim JO; Kim HK; Kim SY; Shin JP
Eur J Pharm Biopharm; 2008 Sep; 70(1):179-86. PubMed ID: 18667297
[TBL] [Abstract][Full Text] [Related]
11. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis.
Sakurai E; Nozaki M; Okabe K; Kunou N; Kimura H; Ogura Y
Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4845-52. PubMed ID: 14578407
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes.
Fialho SL; Rêgo MB; Siqueira RC; Jorge R; Haddad A; Rodrigues AL; Maia-Filho A; Silva-Cunha A
Curr Eye Res; 2006 Jun; 31(6):525-34. PubMed ID: 16769612
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
[TBL] [Abstract][Full Text] [Related]
14. Polylactic acid for visualizing the vitreous body during vitrectomy.
Yamashita T; Sakamoto T; Yamakiri K; Miura M; Enaida H; Ueno A; Atsumi I; Matsuhisa K; Sakamoto Y; Kida T; Ishibashi T
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3277-82. PubMed ID: 17591899
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma.
Velez G; Yuan P; Sung C; Tansey G; Reed GF; Chan CC; Nussenblatt RB; Robinson MR
Arch Ophthalmol; 2001 Oct; 119(10):1518-24. PubMed ID: 11594954
[TBL] [Abstract][Full Text] [Related]
16. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity.
Souza MC; Fialho SL; Souza PA; Fulgêncio GO; Da Silva GR; Silva-Cunha A
Curr Eye Res; 2014 Jan; 39(1):99-102. PubMed ID: 24325382
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis.
Dong X; Shi W; Yuan G; Xie L; Wang S; Lin P
Graefes Arch Clin Exp Ophthalmol; 2006 Apr; 244(4):492-7. PubMed ID: 16163496
[TBL] [Abstract][Full Text] [Related]
19. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants.
Morita Y; Ohtori A; Kimura M; Tojo K
Biol Pharm Bull; 1998 Feb; 21(2):188-90. PubMed ID: 9514619
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
